MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Bristol-Myers Squibb Co.

Открыт

СекторЗдравоохранение

47.62 -1.94

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

46.95

Макс.

48.84

Ключевые показатели

By Trading Economics

Доход

-1.1B

76M

Продажи

442M

12B

P/E

Средняя по отрасли

14.05

57.333

Прибыль на акцию

1.67

Дивидендная доходность

5.04

Рентабельность продаж

0.616

Сотрудники

34,100

EBITDA

-1.9B

2.6B

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+18.22% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

5.04%

2.63%

Дата следующей выплаты дивидендов

1 мая 2025 г.

Следующая эксдивидендная дата

4 июл. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-21B

100B

Предыдущая цена открытия

49.56

Предыдущая цена закрытия

47.62

Техническая оценка

By Trading Central

Уверенность

Neutral Evidence

Bristol-Myers Squibb Co. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 апр. 2025 г., 11:32 UTC

Отчет

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

11 мар. 2025 г., 10:13 UTC

Главные движущие силы рынка
Приобретения, слияния, поглощения

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 мар. 2025 г., 10:13 UTC

Главные движущие силы рынка
Приобретения, слияния, поглощения

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

24 апр. 2025 г., 21:24 UTC

Главные новости
Отчет

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 апр. 2025 г., 14:15 UTC

Главные новости
Отчет

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 апр. 2025 г., 12:37 UTC

Обсуждения рынка
Отчет

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 апр. 2025 г., 11:17 UTC

Отчет

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 апр. 2025 г., 11:13 UTC

Главные новости
Отчет

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q Rev $11.2B >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 1Q EPS $1.20 >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol-Myers Squibb 1Q Net $2.46B >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

24 апр. 2025 г., 10:59 UTC

Отчет

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

14 мар. 2025 г., 09:30 UTC

Главные новости

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Сравнение c конкурентами

Изменение цены

Bristol-Myers Squibb Co. Прогноз

Целевая цена

By TipRanks

18.22% рост

Прогноз на 12 месяцев

Средняя 57.56 USD  18.22%

Максимум 70 USD

Минимум 36 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для Bristol-Myers Squibb Co. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

19 ratings

5

Покупка

13

Удержание

1

Продажа

Техническая оценка

By Trading Central

47.54 / 48.82Поддержка и Сопротивление

Краткосрочная

Neutral Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Strong Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.